Nutra Pharma Corp. Logo

Nutra Pharma Corp.

NPHC

(1.8)
Stock Price

0,00 USD

0% ROA

0% ROE

0x PER

Market Cap.

759.685,00 USD

0% DER

0% Yield

0% NPM

Nutra Pharma Corp. Stock Analysis

Nutra Pharma Corp. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Nutra Pharma Corp. Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (21.41%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 PBV

The stock's low PBV ratio (-0x) suggests it's undervalued, making it an attractive opportunity for investors.

3 DER

The stock has a low debt to equity ratio (-39%), which means it has a small amount of debt compared to the ownership it holds

4 Graham Number

The Graham number of this company suggests that its stock price may be undervalued, indicating a potentially attractive investment opportunity.

5 ROA

The stock's ROA (-444.3%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

7 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Nutra Pharma Corp. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Nutra Pharma Corp. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Buy

Nutra Pharma Corp. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Nutra Pharma Corp. Revenue
Year Revenue Growth
2000 86
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 20.200 100%
2007 0 0%
2008 4.045 100%
2009 618.010 99.35%
2010 1.432.056 56.84%
2011 159.599 -797.28%
2012 203.290 21.49%
2013 122.198 -66.36%
2014 594.505 79.45%
2015 291.302 -104.09%
2016 168.356 -73.03%
2017 120.979 -39.16%
2018 130.596 7.36%
2019 104.393 -25.1%
2020 51.897 -101.15%
2021 97.735 46.9%
2022 436.816 77.63%
2022 0 0%
2023 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Nutra Pharma Corp. Research and Development Expenses
Year Research and Development Expenses Growth
2000 0
2001 0 0%
2002 0 0%
2003 0 0%
2004 1.104.968 100%
2005 224.349 -392.52%
2006 410.920 45.4%
2007 0 0%
2008 0 0%
2009 222.558 100%
2010 191.786 -16.04%
2011 90.865 -111.07%
2012 3.046 -2883.09%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2022 0 0%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Nutra Pharma Corp. General and Administrative Expenses
Year General and Administrative Expenses Growth
2000 0
2001 0 0%
2002 0 0%
2003 1.635.301 100%
2004 0 0%
2005 1.567.941 100%
2006 1.385.971 -13.13%
2007 566.921 -144.47%
2008 1.209.792 53.14%
2009 2.199.146 44.99%
2010 3.945.818 44.27%
2011 0 0%
2012 2.653.696 100%
2013 2.442.471 -8.65%
2014 2.682.479 8.95%
2015 5.991.630 55.23%
2016 1.988.868 -201.26%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2022 0 0%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Nutra Pharma Corp. EBITDA
Year EBITDA Growth
2000 -1.864
2001 -184.344 98.99%
2002 -27.406 -572.64%
2003 -596.426 95.4%
2004 3.205.992 118.6%
2005 -4.375.296 173.27%
2006 -2.362.935 -85.16%
2007 -2.251.066 -4.97%
2008 697.339 422.81%
2009 -1.926.820 136.19%
2010 -3.641.974 47.09%
2011 -3.911.948 6.9%
2012 -2.586.105 -51.27%
2013 -2.346.457 -10.21%
2014 -2.185.680 -7.36%
2015 -5.727.347 61.84%
2016 -2.015.404 -184.18%
2017 -1.375.654 -46.51%
2018 -3.688.914 62.71%
2019 -6.282.867 41.29%
2020 -2.114.452 -197.14%
2021 -11.982.291 82.35%
2022 3.106.284 485.74%
2022 0 0%
2023 0 0%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Nutra Pharma Corp. Gross Profit
Year Gross Profit Growth
2000 86
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 16.728 100%
2007 0 0%
2008 2.988 100%
2009 339.066 99.12%
2010 815.444 58.42%
2011 -719.988 213.26%
2012 55.643 1393.94%
2013 81.033 31.33%
2014 480.205 83.13%
2015 225.497 -112.95%
2016 -54.648 512.64%
2017 94.076 158.09%
2018 14.062 -569.01%
2019 34.715 59.49%
2020 14.916 -132.74%
2021 8.467 -76.17%
2022 272.612 96.89%
2022 0 0%
2023 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Nutra Pharma Corp. Net Profit
Year Net Profit Growth
2000 -1.950
2001 -184.344 98.94%
2002 89.261 306.52%
2003 -2.738.456 103.26%
2004 -7.986.853 65.71%
2005 -5.152.164 -55.02%
2006 -2.431.178 -111.92%
2007 -164.951 -1373.88%
2008 -4.162.108 96.04%
2009 -2.301.641 -80.83%
2010 -3.061.464 24.82%
2011 -4.397.198 30.38%
2012 -3.612.351 -21.73%
2013 -4.342.964 16.82%
2014 -2.532.985 -71.46%
2015 -5.391.981 53.02%
2016 -3.447.613 -56.4%
2017 -4.028.748 14.42%
2018 -3.884.695 -3.71%
2019 -1.661.322 -133.83%
2020 -769.184 -115.98%
2021 -3.465.639 77.81%
2022 2.308.916 250.1%
2022 0 0%
2023 0 0%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Nutra Pharma Corp. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2000 0
2001 0 0%
2002 -2 100%
2003 -3 50%
2004 -6 66.67%
2005 -3 -100%
2006 -1 -200%
2007 0 0%
2008 -1 100%
2009 0 0%
2010 0 0%
2011 -1 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Nutra Pharma Corp. Free Cashflow
Year Free Cashflow Growth
2000 -1.950
2001 -49.994 96.1%
2002 -6 -833133.33%
2003 -78.873 99.99%
2004 -1.512.314 94.78%
2005 -1.558.526 2.97%
2006 -1.746.970 10.79%
2007 -805.367 -116.92%
2008 -976.094 17.49%
2009 -1.964.348 50.31%
2010 -1.430.175 -37.35%
2011 -1.889.471 24.31%
2012 -721.242 -161.97%
2013 -531.037 -35.82%
2014 -169.679 -212.97%
2015 -1.018.906 83.35%
2016 -1.359.880 25.07%
2017 -1.147.460 -18.51%
2018 -999.949 -14.75%
2019 -743.659 -34.46%
2020 -883.991 15.87%
2021 -1.783.512 50.44%
2022 -165.341 -978.69%
2022 0 0%
2023 0 0%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Nutra Pharma Corp. Operating Cashflow
Year Operating Cashflow Growth
2000 -1.950
2001 -49.994 96.1%
2002 -6 -833133.33%
2003 -78.873 99.99%
2004 -1.512.314 94.78%
2005 -1.529.477 1.12%
2006 -1.737.081 11.95%
2007 -805.367 -115.69%
2008 -976.094 17.49%
2009 -1.956.102 50.1%
2010 -1.358.173 -44.02%
2011 -1.888.111 28.07%
2012 -721.242 -161.79%
2013 -531.037 -35.82%
2014 -148.129 -258.5%
2015 -1.018.188 85.45%
2016 -1.356.498 24.94%
2017 -1.138.347 -19.16%
2018 -999.949 -13.84%
2019 -743.659 -34.46%
2020 -878.086 15.31%
2021 -1.744.469 49.66%
2022 -165.341 -955.07%
2022 0 0%
2023 0 0%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Nutra Pharma Corp. Capital Expenditure
Year Capital Expenditure Growth
2000 0
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 29.049 100%
2006 9.889 -193.75%
2007 0 0%
2008 0 0%
2009 8.246 100%
2010 72.002 88.55%
2011 1.360 -5194.26%
2012 0 0%
2013 0 0%
2014 21.550 100%
2015 718 -2901.39%
2016 3.382 78.77%
2017 9.113 62.89%
2018 0 0%
2019 0 0%
2020 5.905 100%
2021 39.043 84.88%
2022 0 0%
2022 0 0%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Nutra Pharma Corp. Equity
Year Equity Growth
2000 0
2001 -134.344 100%
2002 -45.083 -197.99%
2003 3.487.853 101.29%
2004 46.903 -7336.31%
2005 -659.131 107.12%
2006 -1.862.888 64.62%
2007 -1.952.725 4.6%
2008 -2.556.334 23.61%
2009 -1.144.450 -123.37%
2010 -2.526.914 54.71%
2011 -3.911.445 35.4%
2012 -3.576.343 -9.37%
2013 -4.219.449 15.24%
2014 -3.594.761 -17.38%
2015 -3.574.396 -0.57%
2016 -4.476.896 20.16%
2017 -5.410.194 17.25%
2018 -5.936.593 8.87%
2019 -11.701.035 49.26%
2020 -11.493.815 -1.8%
2021 -20.877.650 44.95%
2022 0 0%
2022 -15.609.507 100%
2023 0 0%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Nutra Pharma Corp. Assets
Year Assets Growth
2000 0
2001 1.633.333 100%
2002 819.327 -99.35%
2003 4.439.580 81.54%
2004 593.818 -647.63%
2005 134.941 -340.06%
2006 105.758 -27.59%
2007 144.185 26.65%
2008 107.222 -34.47%
2009 1.252.706 91.44%
2010 753.430 -66.27%
2011 229.305 -228.57%
2012 302.877 24.29%
2013 129.361 -134.13%
2014 387.256 66.6%
2015 387.643 0.1%
2016 214.257 -80.92%
2017 389.570 45%
2018 141.417 -175.48%
2019 339.832 58.39%
2020 301.786 -12.61%
2021 780.022 61.31%
2022 0 0%
2022 690.658 100%
2023 0 0%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Nutra Pharma Corp. Liabilities
Year Liabilities Growth
2000 0
2001 1.767.683 100%
2002 864.410 -104.5%
2003 951.727 9.17%
2004 546.915 -74.02%
2005 794.072 31.13%
2006 1.968.646 59.66%
2007 2.096.910 6.12%
2008 2.663.556 21.27%
2009 2.397.156 -11.11%
2010 3.280.344 26.92%
2011 4.140.750 20.78%
2012 3.879.220 -6.74%
2013 4.348.810 10.8%
2014 3.982.017 -9.21%
2015 3.962.039 -0.5%
2016 4.691.153 15.54%
2017 5.799.764 19.11%
2018 6.078.010 4.58%
2019 12.040.867 49.52%
2020 11.795.601 -2.08%
2021 21.657.672 45.54%
2022 0 0%
2022 16.300.165 100%
2023 0 0%

Nutra Pharma Corp. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
0
Price to Earning Ratio
0x
Price To Sales Ratio
0x
POCF Ratio
0
PFCF Ratio
0
Price to Book Ratio
0
EV to Sales
0
EV Over EBITDA
0
EV to Operating CashFlow
0
EV to FreeCashFlow
0
Earnings Yield
0
FreeCashFlow Yield
0
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
0
Graham NetNet
0

Income Statement Metrics

Net Income per Share
0
Income Quality
0
ROE
0
Return On Assets
0
Return On Capital Employed
0
Net Income per EBT
0
EBT Per Ebit
0
Ebit per Revenue
0
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0
Free CashFlow per Share
0
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
0
Return on Tangible Assets
0
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
0,00
Tangible Book Value per Share
0
Shareholders Equity per Share
0
Interest Debt per Share
0
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
0
Current Ratio
0
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
0
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Nutra Pharma Corp. Dividends
Year Dividends Growth

Nutra Pharma Corp. Profile

About Nutra Pharma Corp.

Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps, and neuropathic pain, as well as a topical gel for treating joint pain, and pain associated with arthritis and repetitive stress; Pet Pain-Away, a homeopathic, non–narcotic, non–addictive, and over–the–counter pain reliever to treat chronic pain in companion animals; Luxury Feet, an over-the-counter pain reliever and anti–inflammatory product to treat pain or discomfort due to high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Pain-Away, an over-the-counter topical pain reliever to relieve pain in horses. It is also involved in developing RPI-78M to treat neurological diseases and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases comprising human immunodeficiency virus/AIDS and herpes, as well as for general anti-viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain. The company was incorporated in 2000 and is based in Plantation, Florida.

CEO
Dr. Michael D. Flax D.D.S., M.
Employee
4
Address
1537 NW 65th Avenue
Plantation, 33313

Nutra Pharma Corp. Executives & BODs

Nutra Pharma Corp. Executives & BODs
# Name Age
1 Joe Lucas
Vice President of Operations
70
2 Dr. Dale Vander Putten MBA, Ph.D.
Chief Scientific Officer
70
3 Dr. Michael D. Flax D.D.S., M.S., P.A.
Chief Executive Officer, Chief Financial Officer & Chairman
70
4 Ms. Nina Goldstein
Secretary
70

Nutra Pharma Corp. Competitors